Poseida to Present P-BCMA-101 Phase 1 Data at the American Association for Cancer Research (AACR) Annual Meeting 2018

Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today announced that initial data from its ongoing P-BCMA-101 Phase 1 study in relapsed/refractory multiple myeloma has been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2018, held April 14-18 in Chicago.